What happened
Samsung Biologics updated a previously disclosed supply contract, now worth US$263M, about 8.81% of its recent annual revenue, running through Mar 2032.
For context, this single contract equals about 8.81% of the company's most recent annual revenue.
| Counterparty | Disclosed |
|---|---|
| Contract value | US$263M |
| vs. recent revenue | 8.81% |
| Through | Mar 2032 (from Jul 2025) |
| Filed | 2026-06-09, [Amended] Supply contract signed |
| Source | DART rcept 20260609800652 → open original filing |
Versions of this filing
- 2026-03-13Original
- 2026-04-10Amendment 1
- 2026-06-09Amendment 2 (this page)
Source: DART. Information only, not investment advice.